Engineering and Preclinical Development of Biological Products that Eliminate HIV-infected Cells (UG3/UH3 Clinical Trial Not Allowed)
ArchivedNational Institutes of Health
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to support the late-stage engineering and preclinical development of innovative biological products that safely and specifically kill HIV-infected cells. Products of interest include but are not limited to broadly neutralizing antibodies (bNAbs), their derivatives, and other soluble, antibody-like molecules.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov
- PostedOct 25, 2023
- ClosesMar 13, 2024
- Award ceiling$500,000
- CFDA93.855
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro